Antisense gets a grip on miR-122 in chimpanzees

Area of Science:

• Hepatology
• Virology
• RNA Therapeutics

Background:

• Hepatitis C virus (HCV) replication is enhanced by microRNA miR-122, a key regulator of liver gene expression.
• Antisense drug design has advanced, improving potency and selectivity for targeted therapies.

Purpose of the Study:

• To evaluate the efficacy and safety of SPC3649, a second-generation antisense RNA molecule targeting miR-122, in an HCV-infected chimpanzee model.
• To explore the therapeutic potential of miR-122 inhibition for treating HCV infection and liver diseases.

Main Methods:

• Chimpanzees infected with HCV were administered 12 weekly intravenous infusions of SPC3649.
• Serum concentrations of HCV RNA and cholesterol were monitored throughout the study.
• Adverse effects were assessed to determine the safety profile of the treatment.

Main Results:

• Treatment with SPC3649 led to significant reductions in serum HCV RNA levels.
• Serum cholesterol concentrations were also decreased in the treated chimpanzees.
• No major adverse events were observed during the 12-week treatment period.

Conclusions:

• SPC3649 demonstrates significant antiviral activity and a favorable safety profile in a preclinical model of HCV infection.
• Targeting miR-122 with antisense oligonucleotides represents a promising therapeutic strategy for HCV and potentially other liver conditions.
• These findings support the advancement of SPC3649 and similar microRNA-targeted antisense drugs into human clinical trials.